Annovis Bio Inc. (ANVS) option IV into data

Annovis Bio Inc. (NYSE: ANVS) 30-day option implied volatility is at 333; compared to its 52-week range of 21 to 333 into topline efficacy data for phase II/III study of buntanetap in patients with mild to moderate Alzheimer's disease is expected in April.

You May Also Be Interested In

• Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
• Burlington Stores (BURL) 3700 contracts of September 25 weekly 305 puts trade
• Collegium Pharma (COLL) 2700 contracts of August 39 calls trade